Daré Bioscience (NASDAQ:DARE) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Daré Bioscience (NASDAQ:DARE) in a report issued on Tuesday,Benzinga reports. HC Wainwright currently has a $12.00 target price on the biotechnology company’s stock.

Daré Bioscience Stock Performance

DARE opened at $3.19 on Tuesday. The company has a market capitalization of $27.75 million, a PE ratio of -5.41 and a beta of 1.27. The stock’s fifty day moving average is $3.55 and its 200-day moving average is $3.71. Daré Bioscience has a one year low of $3.05 and a one year high of $7.56.

Hedge Funds Weigh In On Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC boosted its holdings in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 778,700 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the period. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.